Comparez les meilleurs médecins Thérapie CAR T et les prix en Israël. Trouvez votre meilleure correspondance ici.
Nous sélectionnons à la main les meilleurs médecins selon vos besoins et votre budget.
Examiné médicalement par Fahad Mawlood
Éditeur Médical et Scientifique des DonnéesMeilleurs médecins
14
Israël
Avis
14000+
De vrais patients
Comparez les prix de Thérapie CAR T dans les principaux pays
Touchez un pays pour voir les meilleurs médecins et prix
Obtenez gratuitement des plans de traitement personnalisés et choisissez la meilleure option. Sans engagement · Aucun paiement pour nos services
Montrer d'abord :
Le Dr Ram Ron est spécialisé en thérapie par cellules CAR T au Sourasky Medical Center (Ichilov), apportant une vaste expertise à ce traitement de pointe.
Le Dr Ron Ram a réalisé plusieurs centaines de greffes de cellules souches et a publié plus de 30 articles scientifiques en hématologie et en oncologie.
Cheffe du service d'Oncohématologie Pédiatrique à l'Hôpital pour Enfants Dana Dwek – Le Dr Ronit El Hasid est spécialisée dans les greffes de moelle osseuse et de sang chez les enfants.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Le Dr Michael Shapira est spécialisé en greffe de moelle osseuse au Centre médical Sourasky (Ichilov), avec une vaste expérience dans ce domaine.
Directeur de l'hémato-oncologie pédiatrique au Centre médical Sourasky – spécialisé dans la thérapie par cellules CAR-T pour les enfants atteints de troubles sanguins et de sarcomes.
Fort de 31 ans d'expérience, le Dr Aviv est spécialisé dans la thérapie par cellules CAR T au Centre médical Sourasky (Clinique Ichilov).
Le Dr Yair a apporté des contributions significatives à l'hématologie, en particulier dans le domaine de la leucémie lymphoïde chronique, et est détenteur de nombreuses récompenses et de publications scientifiques.
Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.
She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.
Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.
Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.
She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.
Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.
Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.
He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.
He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.
Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.
He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.
Choisir une clinique à l'étranger peut être stressant. Chez Bookimed, avec plus de 800 000 patients aidés, nous comprenons vos préoccupations. Nous savons comment trouver des médecins de confiance, les meilleures options qualité-prix, et des solutions pour les cas les plus complexes. Nous sommes là pour vous guider à chaque étape.
Yan Matsiivskiy
Responsable de l'équipe de coordination médicale
4300++ parcours patients accompagnés
3 années chez Bookimed
142 patients du Israel ont trouvé leur médecin grâce à nous ce mois-ci
Quiz de 2 minutes
Indiquez-nous votre objectif, budget, délai
Appariement humain + IA
Notre algorithme trouve des correspondances, le coordinateur vérifie l'adéquation
Vos options prêtes
Comparez les prix, forfaits, dates. Discutez avec votre coordinateur
Trop de choix ?
Accompagnement de votre traitement
Coordinateurs médicaux personnels formés
| Classement | Médecin | expérience | Bon choix pour | Ce qui les distingue | Clinique et emplacement | Consultation |
|---|---|---|---|---|---|---|
| #1 | 24 années d'expérience | Thérapie par cellules CAR T | Se spécialise dans les thérapies cellulaires avancées au sein d'un centre d'oncologie de premier plan, en mettant l'accent sur les plans de traitement personnalisés. | Israël | Prix sur demande | |
| #2 | 24 années d'expérience | Hémopathies malignes | Vaste expérience en greffes de cellules souches avec des contributions académiques, incluant plus de 30 articles publiés. Formation spécialisée (Fellowship) effectuée au New York Medical College. | Israël | Prix sur demande | |
| #3 | 38 années d'expérience | Thérapie par lymphocytes T CAR pédiatrique | Dirige le service de transplantation pédiatrique avec plus de 300 transplantations réalisées. A publié plus de 50 articles et est membre d'associations clés en hématologie. | Israël | Prix sur demande | |
| #4 | 36 années d'expérience | Transplantation de moelle osseuse | Spécialisé(e) en transplantation de moelle osseuse, bénéficiant d'une expertise de niveau senior. Formation effectuée au prestigieux Centre médical Hadassah et à l'Université hébraïque. | Israël | Prix sur demande | |
| #5 | 41 années d'expérience | Troubles hématologiques pédiatriques et sarcomes | Dirige le département d'hémato-oncologie pédiatrique de Sourasky – formation reçue dans les meilleurs instituts mondiaux pour les cancers de l'enfant. Coordonne les programmes israéliens de traitement des sarcomes. | Israël | Prix sur demande | |
| #6 | 34 années d'expérience | Thérapie par cellules T CAR | Se spécialise en oncohématologie, avec des décennies d'expérience dans les thérapies cellulaires avancées. Travaille au Sourasky Medical Center, le centre médical de premier plan en Israël. | Israël | Prix sur demande | |
| #7 | 24 années d'expérience | Leucémie lymphoïde chronique | Se spécialise dans la leucémie lymphoïde chronique, avec de multiples prix et subventions de recherche. Membre d'associations d'hématologie de premier plan. | Israël | Prix sur demande |
You do not need a specific CAR T-cell referral to begin. Any hematologist or community oncologist can initiate the process to a specialized center. However, a multidisciplinary team at an accredited Israeli hospital must confirm your final eligibility for treatment.
Bookimed Expert Insight: While any hematologist can refer you, selecting a doctor with a high volume of related procedures speeds up valid documentation. For example, Dr. Ivetta Danylesko at Sheba Medical Center has performed over 3,000 procedures. Working with such experienced specialists helps ensure your medical history meets specific clinical trials or protocol requirements faster.
Patient Consensus: Patients note that pushing a local oncologist to refer directly to a CAR T-cell team can help bypass general queues. Many emphasize that having all previous treatment lines documented is vital for the multi-center board review. It is also common for patients to plan for a three to four month wait even after the initial referral.
Verify Israeli CAR T-cell therapy doctors by confirming their board certification in hematology and oncology through the Scientific Council of the Israel Medical Association. Leading specialists often hold international memberships in the American Society of Hematology and have completed fellowship training at top US institutions.
Bookimed Expert Insight: Data shows that premier Israeli specialists often hold significant leadership roles in global organizations. For instance, Dr. Arnon Nagler at Sheba Medical Center served as the Chair for the European Society for Blood and Marrow Transplantation (EBMT) committees. This level of international leadership indicates that these doctors don't just follow protocols but actually help create the global standards for CAR T-cell therapy and transplant medicine.
Patient Consensus: Patients mention that top-tier doctors are very open about sharing their personal results and response rates. They noticed that experienced specialists often have many co-author credits on major clinical trials. Families emphasize that the most skilled pediatric doctors have deep experience in handling complex cases at dedicated children's hospitals.
When choosing a CAR T-cell therapy doctor in Israel, you should look for board-certified hematologists and oncologists with specialized training in cellular immunotherapy. Leading experts often lead bone marrow transplant departments and have extensive experience in treating complex blood cancers like leukemia and lymphoma.
Bookimed Expert Insight: Data shows that premier Israeli specialists combine clinical leadership with heavy research involvement. For example, Prof. Arnon Nagler at Sheba Medical Center pioneered reduced-intensity transplant protocols. Choosing a doctor who also serves as a department director ensures they oversee the entire cell processing and recovery cycle at JCI-accredited facilities.
Patient Consensus: Patients often emphasize the importance of finding a doctor familiar with bridging therapies used before the actual cell infusion. They note that feeling supported by a team experienced in managing post-infusion side effects made their recovery much smoother. Many were relieved to work with specialists who have personal experience running clinical trials for the latest cellular products.
Major public medical centers in Israel like Sheba and Sourasky (Ichilov) staff board-certified hematologists with international fellowships in cellular immunotherapy. These facilities operate specialized units for CAR T-cell therapy. Experts here maintain credentials from the American Society of Hematology and other global bodies.
Bookimed Expert Insight: Data shows that Israeli public centers often feature surgeons who also lead specialized research departments. For example, Dr. Herishanu Yair at Sourasky heads the CLL Department while managing CAR T-cell protocols. This dual role means patients receive care from doctors who directly contribute to the latest clinical protocols and published research.
Patient Consensus: Patients note that doctors at these centers speak English at a level comparable to US specialists. They often mention the long 6-8 month waitlists for public slots but feel the advanced cellular facilities are worth the wait. Many are surprised by how quickly centers like Sheba can manufacture the cells on-site.
Private CAR T-cell therapy consultations with senior Israeli specialists typically range from $500 to $1,350. The public sector offers significantly lower costs for residents through health funds. However, private sessions provide immediate access to department heads and personalized treatment plans without the long wait times.
Bookimed Expert Insight: Data shows that senior specialists in Tel Aviv often maintain dual roles as department heads and private consultants. Dr. Fredi Aviv and Dr. Herishanu Yair bring over 25 years of experience to these sessions. Choosing a private consult at a center like Sourasky allows patients to bypass the standard 6-month public approval queue.
Patient Consensus: Patients note that while public sector co-pays are minimal, the bureaucracy can delay urgent care. Many choose private sessions to get a treatment plan started in days. They describe the experience as worth the cost for the direct time spent with a professor.
Patients should expect a high level of English proficiency from CAR T-cell therapy specialists in Israel. Most leading doctors hold American Board certifications or have completed fellowships at prestigious institutions like Stanford University and SUNY Brooklyn. Hospitals provide dedicated interpretation services for international patients to navigate complex treatment stages.
Bookimed Expert Insight: Data shows that senior hematologists in Israel often have dual training from both Israeli and North American institutions. For example, Dr. Arnon Nagler at Sheba Medical Center is a Stanford-trained pioneer, while Dr. Ronit El Hasid at Sourasky practiced at City of Hope in Los Angeles. This specific international background means they are comfortable using English as a primary language for medical discussions.
Patient Consensus: Patients find that while lead doctors speak excellent English, some nursing staff may have more limited language skills. Many suggest using a translation app for quick bedside needs but note that hospital coordinators are essential for understanding complex physician instructions.
Israel leads CAR T-cell innovation by running early-phase trials with homegrown constructs for blood cancers and solid tumors. Top experts like Dr. Ron Ram at Sourasky Medical Center (Ichilov) and specialists at Sheba Medical Center develop proprietary vectors. These programs often provide faster access than commercial therapies from the US.
Bookimed Expert Insight: A unique pattern in Israel is the integration of high-level international training within local research clinics. For example, Dr. Ron Ram and Dr. Arnon Nagler both completed fellowships at Stanford University, while Dr. Ronit El Hasid trained at City of Hope. This global expertise allows Israeli centers to successfully run dual US-Israel clinical trials for complex off-the-shelf and bispecific CAR-T products.
Patient Consensus: Patients note that Israeli doctors often provide access to logic-gated constructs after US programs decline their cases. Relatives say the medical teams quickly manage side effects like cytokine release syndrome during phase 1 trials. Many emphasize having a translator ready because consent forms for early-stage studies are frequently in Hebrew.